HK1205450A1 - Medicine comprising combination of general anesthetic drug and hydrogen - Google Patents
Medicine comprising combination of general anesthetic drug and hydrogen Download PDFInfo
- Publication number
- HK1205450A1 HK1205450A1 HK15103729.5A HK15103729A HK1205450A1 HK 1205450 A1 HK1205450 A1 HK 1205450A1 HK 15103729 A HK15103729 A HK 15103729A HK 1205450 A1 HK1205450 A1 HK 1205450A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anesthetic
- hydrogen
- medicine
- general
- hydrogen gas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012125535 | 2012-05-31 | ||
| JP2012-125535 | 2012-05-31 | ||
| PCT/JP2013/065094 WO2013180240A1 (ja) | 2012-05-31 | 2013-05-30 | 全身麻酔薬と、水素とを組み合わせてなる、医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205450A1 true HK1205450A1 (en) | 2015-12-18 |
Family
ID=49673427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103729.5A HK1205450A1 (en) | 2012-05-31 | 2013-05-30 | Medicine comprising combination of general anesthetic drug and hydrogen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150079197A1 (enExample) |
| EP (1) | EP2857026A4 (enExample) |
| JP (1) | JP6168420B2 (enExample) |
| KR (1) | KR20150018832A (enExample) |
| CN (1) | CN104394873A (enExample) |
| AU (1) | AU2013268366A1 (enExample) |
| BR (1) | BR112014029260A2 (enExample) |
| CA (1) | CA2874579A1 (enExample) |
| HK (1) | HK1205450A1 (enExample) |
| IL (1) | IL235718A0 (enExample) |
| IN (1) | IN2014MN02090A (enExample) |
| MX (1) | MX2014014543A (enExample) |
| NZ (1) | NZ701553A (enExample) |
| RU (1) | RU2014152690A (enExample) |
| SG (1) | SG11201407489TA (enExample) |
| WO (1) | WO2013180240A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6253029B2 (ja) * | 2015-01-21 | 2017-12-27 | 大陽日酸株式会社 | 麻酔器用取付キット |
| US20180338995A1 (en) * | 2017-05-23 | 2018-11-29 | Perricone Hydrogen Water Company, Llc | Systems and methods for treatments using hydrogen and/or noble gases |
| US11129848B2 (en) * | 2017-08-08 | 2021-09-28 | Perricone Hydrogen Water Company, Llc | Medication enhancement using hydrogen |
| US20210222174A1 (en) * | 2018-06-29 | 2021-07-22 | John Mansell | Compositions and methods for the treatment of anesthesia-induced neurotoxicity |
| US11123365B2 (en) | 2019-11-18 | 2021-09-21 | Perricone Hydrogen Water Company, Llc | Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof |
| JP7019910B2 (ja) * | 2020-07-21 | 2022-02-16 | ＭｉＺ株式会社 | 薬の副作用、薬の副作用に関連する症状、および／または、治療に伴う副作用を予防および／または改善するための組成物 |
| CN117861037A (zh) * | 2022-10-11 | 2024-04-12 | 上海氢医医疗科技有限公司 | 氢气吸入治疗自闭症 |
| CN119303200A (zh) * | 2024-12-17 | 2025-01-14 | 山东百多安医疗器械股份有限公司 | 一种可以释放氢气减少神经损伤的麻醉机 |
-
2013
- 2013-05-30 MX MX2014014543A patent/MX2014014543A/es unknown
- 2013-05-30 WO PCT/JP2013/065094 patent/WO2013180240A1/ja not_active Ceased
- 2013-05-30 CN CN201380028933.5A patent/CN104394873A/zh active Pending
- 2013-05-30 AU AU2013268366A patent/AU2013268366A1/en not_active Abandoned
- 2013-05-30 NZ NZ701553A patent/NZ701553A/en not_active IP Right Cessation
- 2013-05-30 US US14/397,229 patent/US20150079197A1/en not_active Abandoned
- 2013-05-30 JP JP2014518736A patent/JP6168420B2/ja not_active Expired - Fee Related
- 2013-05-30 BR BR112014029260A patent/BR112014029260A2/pt not_active Application Discontinuation
- 2013-05-30 KR KR20147035945A patent/KR20150018832A/ko not_active Withdrawn
- 2013-05-30 CA CA2874579A patent/CA2874579A1/en not_active Abandoned
- 2013-05-30 RU RU2014152690A patent/RU2014152690A/ru unknown
- 2013-05-30 IN IN2090MUN2014 patent/IN2014MN02090A/en unknown
- 2013-05-30 HK HK15103729.5A patent/HK1205450A1/en unknown
- 2013-05-30 EP EP13796554.7A patent/EP2857026A4/en not_active Withdrawn
- 2013-05-30 SG SG11201407489TA patent/SG11201407489TA/en unknown
-
2014
- 2014-11-16 IL IL235718A patent/IL235718A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150018832A (ko) | 2015-02-24 |
| CA2874579A1 (en) | 2013-12-05 |
| WO2013180240A1 (ja) | 2013-12-05 |
| EP2857026A4 (en) | 2015-11-04 |
| US20150079197A1 (en) | 2015-03-19 |
| BR112014029260A2 (pt) | 2017-06-27 |
| JP6168420B2 (ja) | 2017-07-26 |
| SG11201407489TA (en) | 2014-12-30 |
| MX2014014543A (es) | 2015-06-05 |
| IN2014MN02090A (enExample) | 2015-09-04 |
| NZ701553A (en) | 2016-06-24 |
| RU2014152690A (ru) | 2016-07-20 |
| IL235718A0 (en) | 2015-01-29 |
| EP2857026A1 (en) | 2015-04-08 |
| AU2013268366A1 (en) | 2015-03-19 |
| JPWO2013180240A1 (ja) | 2016-01-21 |
| CN104394873A (zh) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2857026A1 (en) | Medicine comprising combination of general anesthetic drug and hydrogen | |
| Ma et al. | Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain | |
| Wang et al. | Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats | |
| Zou et al. | The effects of L-carnitine on the combination of, inhalation anesthetic-induced developmental, neuronal apoptosis in the rat frontal cortex | |
| Yang et al. | Fluoride activates microglia, secretes inflammatory factors and influences synaptic neuron plasticity in the hippocampus of rats | |
| Gonçalves et al. | Protective role of neuropeptide Y Y2 receptors in cell death and microglial response following methamphetamine injury | |
| Siopi et al. | Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice | |
| Young et al. | Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain | |
| Guimarães et al. | Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial | |
| Samantaray et al. | Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition | |
| Li et al. | Activation of glycine receptors in the lateral habenula rescues anxiety-and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats | |
| Wang et al. | CIH-induced neurocognitive impairments are associated with hippocampal Ca2+ overload, apoptosis, and dephosphorylation of ERK1/2 and CREB that are mediated by overactivation of NMDARs | |
| Logue et al. | Sex-specific effects of social isolation stress and ketamine on hippocampal plasticity | |
| Flores et al. | Neonatal olfactory bulbectomy enhances locomotor activity, exploratory behavior and binding of NMDA receptors in pre-pubertal rats | |
| Haelewyn et al. | Neuroprotection by nitrous oxide: facts and evidence | |
| Figueiredo et al. | Alpha-linolenic acid treatment reduces the contusion and prevents the development of anxiety-like behavior induced by a mild traumatic brain injury in rats | |
| Harding et al. | Prenatal exposure to valproic acid and treatment with intranasal oxytocin have sex-specific effects on behavior in Long Evans rats | |
| Tourrel et al. | The antiapoptotic effect of remifentanil on the immature mouse brain: an ex vivo study | |
| Zhao et al. | Morphine pretreatment protects against cerebral ischemic injury via a cPKCγ-mediated anti-apoptosis pathway | |
| Zoladz et al. | Ketamine sex-and dose-dependently mitigates behavioral sequelae induced by a predator-based psychosocial stress model of post-traumatic stress disorder | |
| Lee et al. | Inhibition of hexokinase leads to neuroprotection against excitotoxicity in organotypic hippocampal slice culture | |
| Nahas et al. | Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats | |
| Sivandzade | Traumatic Brain Injury: Assessing the Pathogenic Impact of Chronic Smoking and Potential Countermeasures | |
| Franken | Refractory nerve agent induced seizures: the role of GABA (A) receptors and oxidative stress | |
| Guo et al. | Effect of Parecoxib on Hippocampus and Hypothalamic Orexin Neurons in Rats with Cerebral Infarction |